Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert - The Market Herald

" Rhythm Biosciences (ASX:RHYS) adds Sonic Clinical Services to ColoSTAT clinical trial

Rhythm Biosciences (RHY) has added the primary care division of medical giant Sonic Healthcare (SHL) to its ColoSTAT clinical trial.
Orthocell (ASX:OCC) - CEO Paul Anderson with intern Margeux Steltz - The Market Herald

" Orthocell (ASX:OCC) secures Chinese and NZ patents

Regenerative medicine company Orthocell (OCC) has secured Chinese and New Zealand patents for its novel CelGro collagen medical device for soft tissue regeneration.
Patrys (ASX:PAB) - - The Market Herald

" Study finds Patrys’ (ASX:PAB) candidate could slow brain cancer

A new study featuring Patrys’ (PAD) PAT-DX1 candidate has demonstrated its ability to inhibit the growth of primary and secondary brain cancers.
Avita Medical (ASX:AVH) - CEO, Mike Perry - The Market Herald

" Avita Medical (ASX:AVH) boosts fourth-quarter revenue forecast

With the prevailing strength of its RECELL System, Avita Medical (AVH) has elected to increase its fourth-quarter revenue guidance.
Nyrada (ASX:NYR) - CEO, James Bonnar - The Market Herald

" Nyrada’s (ASX:NYR) new drug advances to efficacy studies

Nyrada’s (NYR) new lead drug candidate has advanced to efficacy studies with the Walter Reed Army Institute of Research (WRAIR).
Zelira Therapeutics (ASX:ZLD) - CEO, Dr Oludare Odumosu - The Market Herald

" Zelira Therapeutics (ASX:ZLD) to launch CBD toothpaste in the UK

Zelira Therapeutics (ZLD) has signed a five-year distribution with Health House International (HHI) to launch CBD toothpaste in the UK.
Kazia Therapeutics (ASX:KZA) - CEO & Executive Director, Dr James Garner - The Market Herald

" Kazia Therapeutics (ASX:KZA) to trial brain cancer treatment alongside keto diet

Kazia Therapeutics (KZA) will collaborate with Cornell University to investigate Kazia’s new brain cancer treatment in combination with a keto diet.
MRC and University of Adelaide create methods to produce Graphene

" Invex Therapeutics (ASX:IXC) receives US FDA feedback for hypertension treatment

Invex Therapeutics (IXC) is reviewing its upcoming Presendin hypertension treatment trial after receiving feedback from the US Food and Drug Administration.
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson - The Market Herald

" Anteris Technologies (ASX:AVR) study validates tissue technology

Gabon-focussed iron ore company Genmin (ASX:GEN) lists on ASX

" Argenica Therapeutics (ASX:AGN) lists on ASX

Argenica Therapeutics (AGN) has finished its first day of trade on the ASX, following a well supported initial public offering.